RPTX (Repare Therapeutics) Operating Margin %: -3.70% (As of Sep. 2025)


RPTX Repare Therapeutics Inc RPTX
20 GF Score
Price $2.65
GF Value $0.94
! 6 Warning Signs
View Full Analysis

What is Repare Therapeutics Operating Margin %?

Repare Therapeutics RPTX 20 Operating Margin % is -3.70% as of Sep. 2025. GuruFocus rates RPTX with a GF Score™ of 20/100 and a GF Value™ of $0.94. The stock has 6 warning signs investors should review.

Operating Margin % is calculated as Operating Income divided by its Revenue. Repare Therapeutics's Operating Income for the three months ended in Sep. 2025 was $-0.43 Mil. Repare Therapeutics's Revenue for the three months ended in Sep. 2025 was $11.62 Mil. Therefore, Repare Therapeutics's Operating Margin % for the quarter that ended in Sep. 2025 was -3.70%.

The historical rank and industry rank for Repare Therapeutics's Operating Margin % or its related term are showing as below:

RPTX' s Operating Margin % Range Over the Past 10 Years
Min: -40223.7   Med: -227.3   Max: -15.02
Current: -667.31


RPTX's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -86.77 vs RPTX: -667.31

Repare Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Repare Therapeutics's Operating Income for the three months ended in Sep. 2025 was $-0.43 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2025 was $-79.21 Mil.


Repare Therapeutics  (NAS:RPTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Repare Therapeutics Operating Margin % Related Terms


Repare Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Repare Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repare Therapeutics Operating Margin % Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial -40,223.70 -1,429.74 -15.02 -227.30 -172.31

Repare Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -8,024.80 -3.70

RPTX vs MGNX, THAR, ANIX: Operating Margin % Comparison

For the Biotechnology subindustry, Repare Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repare Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Operating Margin % falls into.


RPTX
20GF Score
Repare Therapeutics Inc RPTX
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repare Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Repare Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-92.144 / 53.477
=-172.31 %

Repare Therapeutics's Operating Margin % for the quarter that ended in Sep. 2025 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2025 ) / Revenue (Q: Sep. 2025 )
=-0.43 / 11.62
=-3.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -3.70% mean?
Repare Therapeutics (RPTX) has a Operating Margin % of -3.70% as of Sep. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Repare Therapeutics and its competitors.
Is Repare Therapeutics' Operating Margin % too high?
Repare Therapeutics' current Operating Margin % is -3.70%. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' Operating Margin % compare to MGNX and THAR?
Repare Therapeutics' Operating Margin % of -3.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Repare Therapeutics and its competitors. Repare Therapeutics's current Operating Margin % is -3.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current Operating Margin % of -3.70%. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current Operating Margin % is -3.70%. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current Operating Margin % is -3.70% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repare Therapeutics (RPTX) Overvalued in 2026?

Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued. The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.

Key valuation signals for RPTX:

  • Operating Margin %: -3.70%
  • GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
  • GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Repare Therapeutics Business Description

Address 7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score

Get the complete analysis for RPTX

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$0.94
GF Value